“Carcinoma de pulmón célula no pequeña: ¿hay diferencias por histología utilizando inmunoterapia?” - page 7

NSCLC development
Pretreated advanced 1st -line advanced
ORR PFS OS ORR PFS OS
Nivolumab
SQ
Non-SQ
20% vs 8%
19% vs 12%
3.5 m vs 2.8 m
2.3 m vs 4.2 m
9.2 vs 6.0 m
12.2 vs 9.4 m
26.1% vs 33.5 m 4.2 vs 5.9 m 14.4 vs 13.2 m
Pembrolizumab 18-18% vs 9% 3.9-4 m vs 4 m 10.4-12-7 vs 8.5 m 44.8 % vs 27.8% 10.3 vs 6 m NR
Atezolizumab 14%vs 13% 2.8 vs 4 m 13.8 vs 9.6 m
Introduction
Borghaei H et al NEJM 2015; Brahmer J NEJM 2015; Herbst R S et al Lancet 2015; Rittmeyer, A. Lancet 2016;
Socinsky M A ESMO 2016